SAN RAFAEL, Calif., Nov. 6, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D Day at 8:00am ET on Thursday, November 14, 2019. BioMarin management and external experts will provide an update to the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare diseases.
BioMarin R&D Day 2019 Agenda
Welcome and Opening Remarks
Vosoritide for Achondroplasia and Other Indications
R&D Pipeline Deep Dive including PKU Gene Therapy Program Update
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Closing Statements
Live Audio WebcastInterested parties may access a live audio webcast that will include audio and slides of the presentations here. A replay of the event will be archived on the Events and Presentations page under the Investors/Media section of the Company's website for at least two weeks following the event.
For those who choose not to listen to the event via webcast, dial-in information for the audio portion of the webcast can be accessed using:
USA: (913) 227-1201USA /Canada (toll free): (866) 705-2554Conference ID: 6342187
About BioMarinBioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.
View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-highlight-innovative-development-pipeline-at-rd-day-on-november-14th-300953214.html
SOURCE BioMarin Pharmaceutical Inc.